J&J has a long Rybrevant road ahead

For the first time, Johnson & Johnson has split out sales of Rybrevant – kind of. In its first-quarter earnings on Tuesday, the company disclosed revenues for the anti-EGFR x cMet bispecific, but only alongside its oral EGFR-TKI Lazcluze. Sales of the combo, which is approved for first-line EGFR-mutated NSCLC, totalled $327m in 2024. Presumably Rybrevant revenues are negligible in its other indications, NSCLC with EGFR exon 20 insertions, and alongside chemo in second-line EGFR-mutated NSCLC. One thing is clear: Rybrevant has a long way to go to meet J&J’s $5bn peak revenue forecast. In the nearer term, the company said it expected sales to be at least twice as high as analyst estimates of $1.8bn in 2027, suggesting an internal forecast of $3.6bn that year. Rybrevant is taking on AstraZeneca’s Tagrisso, against which it recently showed a survival benefit in the Mariposa trial. Tagrisso plus chemo could be the more relevant rival, although the Flaura2 trial of that regimen hasn’t yet reported OS data. Toxicity will be a factor, with Rybrevant linked with severe rash and venous thromboembolic events; concerns J&J hopes to mitigate in its ongoing Copernicus trial. Tagrisso sold $6.6bn in 2024.

Rybrevant + Lazcluze vs Tagrisso sales

Source: Company releases.